December 10, 2021
CASI Pharmaceuticals And Bioinvent Announce CTA Approval For Clinical Study Of BI-1206 In NHL In ChinaNovember 15, 2021
CASI Pharmaceuticals To Present At Jefferies London Healthcare ConferenceNovember 12, 2021
CASI Pharmaceuticals Announces Third Quarter 2021 Financial ResultsNovember 05, 2021
CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021November 02, 2021
CASI Pharmaceuticals To Report Third Quarter 2021 Financial Results And Host Conference Call November 12, 2021October 25, 2021
CASI Pharmaceuticals Announces Partner Juventas Completion Of Series C Financing Of $63 Million (RMB410 Million) For Acceleration Of CNCT19 Pivotal Trials And CommercializationSeptember 20, 2021
CASI Pharmaceuticals, Inc. To Participate In Oppenheimer Fall Healthcare Life Sciences & MedTech SummitAugust 12, 2021
CASI Pharmaceuticals Announces Second Quarter 2021 Financial ResultsAugust 10, 2021
CASI Pharmaceuticals To Report Second Quarter 2021 Financial Results And Host Conference Call August 12, 2021June 10, 2021
CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple MyelomaMay 27, 2021
CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare ConferenceMay 13, 2021
CASI Pharmaceuticals Announces First Quarter 2021 Financial ResultsMay 11, 2021
CASI Pharmaceuticals To Report First Quarter 2021 Financial Results And Host Conference Call May 13, 2021March 30, 2021
CASI Pharmaceuticals Announces Full Year 2020 Financial ResultsMarch 24, 2021
CASI Pharmaceuticals Announces Pricing Of $32,500,000 Public Offering Of Common StockMarch 23, 2021
CASI Pharmaceuticals Announces Proposed Public Offering Of Common StockMarch 11, 2021
CASI Pharmaceuticals To Host Business Update Call March 12, 2021March 08, 2021
Cleave Therapeutics Licenses First-in-Class VCP/P97 Inhibitor CB-5339 To CASI Pharmaceuticals For Greater China RegionFebruary 16, 2021
CASI Pharmaceuticals Announces Preliminary Fourth Quarter And Full-Year 2020 Revenues And Provides Business UpdatesJanuary 28, 2021
CASI Pharmaceuticals Partner, BioInvent, Presents Phase I/IIA Data That Suggests BI-1206 Restores Activity Of Rituximab In Relapsed Non-Hodgkin’s Lymphoma Patients
